Burnet Institute is an Australian, unaligned, independent, not-for-profit, medical research and public health organisation. Our mission is to improve the health of disadvantaged or otherwise vulnerable people throughout the world.
Burnet Institute’s Eliminate Hep C Program will address some of the key global priorities and build upon ground breaking biomedical research, modelling and analysis that demonstrates both the feasibility and public health benefit of eliminating hepatitis C.
Working together, with research organisations, governments, the community and affected populations, our Eliminate Hep C Program will help change the course of hepatitis C infection and its impact as a public health threat.
With the listing of direct-acting antiviral (DAA) drugs on the PBS, eliminating hepatitis C virus in Australia is now a possibility. This is just one step on the ambitious path to elimination. Elimination will require four ‘pillars’ of intervention - harm reduction, vaccine development, testing and treatment strategies. Cross-cutting these interventions are awareness raising, education and training, reducing stigma, and strengthened surveillance.
The Treatment as Prevention (TAP) Study is examining the feasibility of treating people who inject drugs in a community-based setting and measuring the effectiveness of using a social network-based approach.
The PRIME Study is a randomised study comparing hepatitis C treatment in a primary health care service with a hospital setting.
The Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals study (the co-EC Study) aims to test, treat and cure gay and bisexual men who are infected with both hepatitis C and HIV, and measure the impact on hepatitis C infection and re-infection.
The Eliminate Hepatitis C Study (the EC Study) involves the establishment of nurse-led hepatitis C treatment programs in community settings to increase treatment uptake among people who inject drugs.
The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) is the only system in Australia capable of capturing clinical and laboratory data on HCV testing, providing the ability to measure the population-level impact of treating HCV infection. The ACCESS system was designed and is operated by Burnet Institute and is now funded for expansion nationally.
HepSeeVax (HepSeeVaxDelta3TM) is a preventative vaccine in late preclinical development by Burnet's researchers in the Viral Entry and Vaccines Laboratory led by Associate Professor Heidi Drummer. Vaccines will be essential for a global hepatitis C elimination program.